545 related articles for article (PubMed ID: 34370973)
1. Prostate cancer.
Sandhu S; Moore CM; Chiong E; Beltran H; Bristow RG; Williams SG
Lancet; 2021 Sep; 398(10305):1075-1090. PubMed ID: 34370973
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
3. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.
Toren PJ; Gleave ME
Asian J Androl; 2013 May; 15(3):342-9. PubMed ID: 23584378
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
5. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
Antonarakis ES; Drake CG
Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
8. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
9. Management of prostate cancer. Part 3: metastatic disease.
Shah J; Khaksar SJ; Sooriakumaran P
Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
[TBL] [Abstract][Full Text] [Related]
10. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
Gamat M; McNeel DG
Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
[TBL] [Abstract][Full Text] [Related]
12. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
Garcia JA; Rini BI
Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
[TBL] [Abstract][Full Text] [Related]
13. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for the treatment of advanced prostate cancer.
Clarke JM; Armstrong AJ
Curr Treat Options Oncol; 2013 Mar; 14(1):109-26. PubMed ID: 23322116
[TBL] [Abstract][Full Text] [Related]
15. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
Saluja R; Cheung P; Zukotynski K; Emmenegger U
Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
[TBL] [Abstract][Full Text] [Related]
16. Navigating systemic therapy for metastatic castration-naïve prostate cancer.
Kwan EM; Thangasamy IA; Teh J; Alghazo O; Sathianathen NJ; Lawrentschuk N; Azad AA
World J Urol; 2021 Feb; 39(2):339-348. PubMed ID: 31897602
[TBL] [Abstract][Full Text] [Related]
17. [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
Rozet F; Hennequin C; Beuzeboc P; Mathieu R; Mongiat-Artus P; Beauval JB; Cormier L; Fromont-Hankard G; Ploussard G; Renard-Penna R; Brureau L; Méjean A
Prog Urol; 2020; 30(8-9):430-438. PubMed ID: 32517891
[TBL] [Abstract][Full Text] [Related]
18. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
19. New developments in the medical management of prostate cancer.
Kohli M; Tindall DJ
Mayo Clin Proc; 2010 Jan; 85(1):77-86. PubMed ID: 20042563
[TBL] [Abstract][Full Text] [Related]
20. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
